Merck (MRK) to Strengthen Cancer Pipeline With Harpoon Buyout

Merck (MRK) announced a definitive agreement to acquire Harpoon Therapeutics (HARP) for an approximate total equity value of $680 million.The acquisition will strengthen Merck’s oncology pipeline by adding south San Francisco-based Harpoon Therapeutics’ novel class of T cell engagers, which it is developing by leveraging its proprietary Tri-specific T cell Activating Construct platform. The T cell engagers are designed to remain inactive till they reach the tumor.The company has made significant progress in ...